# Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

> **NCT03642847** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 104 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** Prevnar 13
- **BIOLOGICAL:** multivalent pneumococcal conjugate formulation 1
- **BIOLOGICAL:** multivalent pneumococcal conjugate formulation 2

## Key facts

- **NCT ID:** NCT03642847
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-29
- **Primary completion:** 2019-03-29
- **Final completion:** 2019-03-29
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2019-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03642847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03642847, "Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03642847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*